Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $5.77.
Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Monday, November 11th.
Check Out Our Latest Stock Analysis on CTMX
CytomX Therapeutics Price Performance
CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $33.43 million during the quarter, compared to analyst estimates of $18.92 million. During the same period last year, the company posted $0.04 EPS. Sell-side analysts anticipate that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CTMX. Jacobs Levy Equity Management Inc. lifted its position in CytomX Therapeutics by 1.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 16,359 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of CytomX Therapeutics by 10.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after purchasing an additional 26,373 shares during the period. US Bancorp DE acquired a new stake in CytomX Therapeutics during the 3rd quarter worth approximately $40,000. Geode Capital Management LLC boosted its stake in CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after purchasing an additional 34,032 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in CytomX Therapeutics by 1.4% in the 2nd quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock valued at $3,324,000 after buying an additional 37,739 shares in the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Featured Stories
- Five stocks we like better than CytomX Therapeutics
- Following Congress Stock Trades
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- What Are the U.K. Market Holidays? How to Invest and Trade
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- 3 Warren Buffett Stocks to Buy Now
- The Next 2 AI Winners Have Triple-Digit Upside Potential
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.